Dalli confirms policy change on choice of reference product for biosimilars in EU
This article was originally published in SRA
In a move that will be welcomed by developers of biosimilar pharmaceutical products, EU health and consumer policy commissioner John Dalli has confirmed that marketing applications that contain clinical data relating to reference products that are not sourced from the EU will be allowed1.
You may also be interested in...
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.